Source: Pharmaceutical Medicine. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, TERAPIA COMBINADA, QUIMIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIMENTEL, Franklin Fernandes et al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, v. 32, n. 5, p. 319-325, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40290-018-0247-5. Acesso em: 23 jul. 2024.APA
Pimentel, F. F., Morgan, G., Tiezzi, D. G., & Andrade, J. M. de. (2018). Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, 32( 5), 319-325. doi:10.1007/s40290-018-0247-5NLM
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2024 jul. 23 ] Available from: https://doi.org/10.1007/s40290-018-0247-5Vancouver
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.[citado 2024 jul. 23 ] Available from: https://doi.org/10.1007/s40290-018-0247-5
